Stocktake

Correction or not, investors may need to “buckle up for more volatility” following the recent “market rout”, Blackrock recently cautioned. Two (...)

Valeant Pharmaceuticals  offered to buy Allergan, maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion in the latest step of the Canadian company’s plan to become one of the world’s largest drugmakers. Photographer: Patrick T. Fallon/Bloomberg

Valeant Pharmaceuticals said it began an exchange offer for Botox maker Allergan, taking its hostile $50.8 billion bid directly to shareholders. Que(...)

The head offices of Valeant Pharmaceuticals  in Laval, Quebec. The Canadian-based company said Allergan’s refusal to enter talks left it with no option but to go hostile in the battle for control of its US rival. Photograph: Christinne Muschi/Reuters

Valeant Pharmaceuticals is preparing to take its bid for Allergan direct to shareholders after its latest $53 billion offer was rejected by the mak(...)

A drop of Allergan Inc Botox is seen on the tip of a needle. Valeant’s new offer included a contingent value right that could be worth an extra $7.6 billion. Photograph: Bloomberg

The battle for Botox-maker Allergan took a new twist yesterday when Canadian drugs firm Valeant sold off its skin fillers business, giving it the fir(...)

Dr Keith Marcus injects Botox between a patient’s eyes. Valeant Pharmaceuticals International has offered to buy Allergan, the maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion. Photographer: Patrick  Fallon/Bloomberg

US drugmaker Allergan today rejected Valeant Pharmaceuticals International’s $47 billion takeover offer, saying its proposed cost cuts were too steep.(...)

Pfizer’s plan to move its domicile to Britain by acquiring AstraZeneca would lower its taxes. Photograph: getty images

Rumours about a massive healthcare deal were circulating in industry circles, months before Pfizer disclosed its $100 billion pursuit of Britain’s Ast(...)

Zimmer, the maker of the eponymous walking frame, has agreed to acquire Biomet for $13.35 billion, combining the two ­providers of medical prod(...)

Joe Jimenez: refocusing Novartis on pharmaceuticals, eyecare and generics

A near $50 billion (€36 billion) takeover battle for the maker of Botox and a multibillion-dollar asset swap between Novartis and Glaxo-SmithKline (...)

AstraZeneca shares surged by 8 per cent at one stage amid frenzied speculation that US rival Pfizer was preparing a mega-bid. Photograph: Chris Ratcliffe/Bloomberg

A flurry of deals and speculation of more to come has set the pharmaceuticals sector alight, sending shares in some of the UK’s biggest drugs g(...)

With half the country supposedly in convulsions over the Arthur’s Day stereotyping of the Irish as drunks (or maybe it’s just half of Twitter), an ema(...)